Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 22, Number 1—January 2016

Research

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013

Ross L. CameronComments to Author , Kimberley Kavanagh, Jiafeng Pan, John Love, Kate Cuschieri, Chris Robertson, Syed Ahmed, Timothy Palmer, and Kevin G.J. Pollock
Author affiliations: Health Protection Scotland, Glasgow, Scotland, UK (R.L. Cameron, J. Love, S. Ahmed, K.G.J. Pollock); University of Strathclyde, Glasgow (K. Kavanagh, J. Pan, C. Robertson); Scottish Human Papillomavirus Reference Laboratory, Edinburgh, Scotland, UK (K. Cuschieri); University of Edinburgh, Edinburgh (T. Palmer)

Main Article

Table 7

Prevalence and odds of infection with high-risk HPV excluding vaccine and cross-protective types and for any HPV among nonvaccinated women, by study year, Scotland, 2009–2013*

Study year No. women High-risk HPV excluding vaccine 
and cross-protective types†
Any HPV
No. pos % Pos (95% CI) OR (95% CI) No. pos % Pos (95% CI) OR (95% CI)
2009 1.652 473 28.6 (26.5–30.9) 1 946 57.3 (54.9–59.6) 1
2010 1,012 338 33.4 (30.6–36.4) 1.26 (1.07–1.5) 578 57.1 (54.0–60.1) 0.99 (0.85–1.16)
2011 557 210 37.7 (33.8–41.8) 1.50 (1.22–1.83) 354 59.5 (59.5–67.4) 1.30 (1.07–1.59)
2012 245 90 36.7 (30.9–42.9) 1.44 (1.09–1.91) 166 61.7 (61.7–73.3) 1.56 (1.18–2.09)
2013 198 65 32.8 (26.7–39.6) 1.20 (0.87–1.64) 118 52.6 (53.6–66.2) 1.10 (0.82–1.49)

*HPV, human papillomavirus; OR, odds ratio; pos, positive.
†HPV 35, 39, 51, 52, 56, 58, 59, or 68.

Main Article

TOP